Acetylcholinesterase (AChE) inhibitors are a class of drugs commonly used for the treatment of Alzheimer's Disease (AD) and other forms of dementia. AChE inhibitors work by blocking the enzyme AChE, which breaks down the neurotransmitter acetylcholine. By blocking the enzyme, AChE inhibitors help increase concentrations of the neurotransmitter, thereby improving cognitive function and reducing the effects of memory loss associated with Alzheimer's Disease. The four main types of AChE inhibitors used in the treatment of AD and other dementia-related disorders are donepezil, rivastigmine, galantamine, and tacrine. Donepezil is the most commonly-prescribed AChE inhibitor due to its wide safety profile and relatively long duration of action. However, each of the four drugs have their own unique set of side effects and potential interactions with other medications, so it is important for patients to discuss all available options with their physician. Common side effects associated with AChE inhibitors include headaches, nausea, fatigue, diarrhea, dizziness, and weight loss, while more serious side effects may include an increased risk of intestinal and urinary tract infections, as well as an increased risk of stroke or heart attack. It is therefore important to discuss any risk factors or underlying health conditions with your physician before starting an AChE inhibitor medication. Overall, AChE inhibitors have been found to be effective in improving cognitive function and memory in AD and other forms of dementia, though the exact mechanism behind their effects is still largely unknown. While the drugs may be associated with a range of side effects, the potential benefits in terms of improved cognitive function often far outweigh the risks for dementia patients.
Title : Novel important cellular responses, signaling mechanisms and therapeutic options in vascular dementia
Yong Xiao Wang, Albany Medical College, United States
Title : TBI updates in 2025
Jonathan Eskenazi, Cedars Sinai / UCLA, United States
Title : A case of vile vindictive primary CNS vasculitis
George Diaz, Memorial Healthcare Systems, United States
Title : Non-pharmacological strategies to counteract oxaliplatin toxicity: Protective effects of vagal nerve stimulation and resistance training on neuropathy, motor dysfunction, and muscle atrophy
Ricardo Aparecido Baptista Nucci, Hospital Sirio-Libanes, Brazil
Title : Synapticare: Integrating sleep data and tau biomarkers to assess depression severity
Medha Menon, John Foster Dulles HS, United States
Title : How have we eliminated infection: From the bone to brain?
Thomas J Webster, Interstellar Therapeutics, United States